If you've spent any time comparing IGF-1 analogues for a research protocol, you've probably hit the same wall: two peptides with similar names, overlapping literature, and vendor pages that describe both as "the more potent version of IGF-1" without explaining why. That's not a helpful place to make a purchasing or protocol decision from.
Featured Product
IGF-1 LR3 and IGF-1 DES are both modified analogues of insulin-like growth factor 1, engineered to resist binding proteins that would otherwise clear native IGF-1 from a research system quickly. But they get there through different structural changes, and those changes produce measurably different half-lives, binding behavior, and practical handling requirements. Confusing the two — or assuming they're interchangeable — can affect the reproducibility of an in vitro study before a single data point is collected.
This guide breaks down what separates IGF-1 LR3 from IGF-1 DES: molecular structure, receptor and binding-protein interaction, stability once reconstituted, and the research contexts where each analogue tends to show up in the literature. You'll also find a side-by-side comparison table, storage and purity guidance, and answers to the questions researchers ask most often before selecting an IGF-1 analogue for a study.
Research Use Only IGF-1 LR3 and IGF-1 DES, as sold by 99 Purity Peptides, are research chemicals intended strictly for laboratory and in-vitro research use. They are not drugs, dietary supplements, or products for human or animal consumption, and nothing in this article should be read as a recommendation for personal use. |
What Is IGF-1 LR3?
IGF-1 LR3 (Long Arg3-IGF-1) is a synthetic 83-amino-acid analogue of insulin-like growth factor 1. It's built from native IGF-1 with two modifications: a 13-amino-acid extension added to the N-terminus, and a substitution of arginine for glutamic acid at the third amino acid position. Both changes target the same problem — native IGF-1 binds tightly to insulin-like growth factor binding proteins (IGFBPs) in solution, which limits how much free, bioactive peptide is available in a research system.
Because the structural changes in IGF-1 LR3 reduce its affinity for IGFBPs, more of the peptide stays biologically active and available to interact with the IGF-1 receptor over time. In practical terms, that gives IGF-1 LR3 a substantially longer functional half-life than unmodified IGF-1 — a property researchers frequently cite when selecting it for extended in vitro cell-signaling or proliferation studies.
- Molecular weight: approximately 9,117 Da
- Sequence length: 83 amino acids
- Key modification: N-terminal 13-amino-acid extension + Arg3 substitution
- Primary research relevance: reduced IGFBP binding, extended activity window
What Is IGF-1 DES?
IGF-1 DES (Des(1-3)-IGF-1) takes the opposite structural approach. Instead of adding amino acids, it removes the first three amino acids from the N-terminus of native IGF-1, producing a truncated 67-amino-acid analogue. That N-terminal region is exactly where IGFBPs make their primary contact with the IGF-1 molecule, so removing it sharply reduces binding-protein affinity as well — through subtraction rather than extension.
The practical effect is a peptide that researchers often describe as having higher relative potency at the IGF-1 receptor in short-window assays, because a larger fraction of the administered peptide is immediately free and receptor-available rather than protein-bound. The tradeoff is stability: DES(1-3)-IGF-1 is generally reported as less stable in solution and has a shorter functional half-life than IGF-1 LR3, which shapes how it's used and how quickly it needs to be used after reconstitution.
- Molecular weight: approximately 7,649 Da
- Sequence length: 67 amino acids
- Key modification: N-terminal truncation (removal of first 3 amino acids)
- Primary research relevance: reduced IGFBP binding, higher short-term receptor availability
IGF-1 LR3 vs IGF-1 DES: Key Differences at a Glance
Featured Snippet Answer: IGF-1 LR3 and IGF-1 DES are both IGFBP-resistant IGF-1 analogues, but LR3 uses an N-terminal extension for a longer half-life and steadier activity, while DES uses an N-terminal truncation for higher short-term receptor availability and a shorter, more concentrated activity window.
Attribute | IGF-1 LR3 | IGF-1 DES |
|---|---|---|
Full name | Long Arg3-IGF-1 | Des(1-3)-IGF-1 |
Structural change | 13-amino-acid N-terminal extension + Arg3 substitution | N-terminal truncation (first 3 amino acids removed) |
Amino acids | 83 | 67 |
Approx. molecular weight | 9,117 Da | 7,649 Da |
IGFBP binding affinity | Very low | Very low |
Relative functional half-life | Longer (extended activity window) | Shorter (rapid but brief activity window) |
Reported research emphasis | Sustained cell-signaling / proliferation studies | High receptor-availability / short-window assays |
Solution stability once reconstituted | Comparatively more stable | Comparatively less stable |
Typical research handling | Standard cold-chain, refrigerate after reconstitution | Cold-chain plus prompt use after reconstitution |
Molecular Structure & Mechanism of Action
10.1 Why Structure Drives Behavior
Both analogues exist because of the same underlying research problem: native, unmodified IGF-1 is tightly regulated in solution by six known IGFBPs, which bind it with high affinity and control how much free peptide is available to interact with the IGF-1 receptor (IGF-1R). For researchers studying IGF-1 signaling pathways directly, that regulation is a confound — it makes dosing and exposure harder to predict in an in vitro system. IGF-1 LR3 and IGF-1 DES were both developed to sidestep it, just from opposite structural directions.
10.2 Long Arg3-IGF-1 (LR3)
The added 13-amino-acid N-terminal sequence in IGF-1 LR3 sterically interferes with IGFBP binding without significantly altering the peptide's affinity for the IGF-1 receptor itself. The additional Arg3 substitution further reduces residual binding-protein interaction. The result is a larger, structurally distinct molecule that still activates IGF-1R-mediated signaling — commonly referenced in the literature in the context of the IGF-1/PI3K/Akt signaling pathway — while remaining largely free from IGFBP sequestration.
10.3 Des(1-3)-IGF-1 (DES)
IGF-1 DES achieves a similar functional outcome by removing the exact N-terminal residues that IGFBPs use for high-affinity binding. Because the truncation is smaller and more targeted than LR3's extension, DES more closely resembles the size and shape of native IGF-1 — which some researchers cite as a reason it's used in studies where structural similarity to endogenous IGF-1 is a design consideration.
Half-Life & Stability Comparison
Half-life is the single most commonly cited differentiator between these two analogues in research contexts, and it's a direct consequence of the structural differences above.
- IGF-1 LR3's extended structure and very low IGFBP affinity give it the longer functional half-life of the two analogues, which is why it's frequently selected for research designs that need activity to persist over an extended observation window.
- IGF-1 DES's shorter half-life reflects both its reduced IGFBP protection and its closer structural similarity to native IGF-1, which is more rapidly cleared in biological systems even without binding-protein sequestration.
- Once reconstituted, both peptides are temperature- and freeze-thaw-sensitive. DES is generally regarded as the less stable of the two in solution and benefits from being used closer to the point of reconstitution.
Quick Answer IGF-1 LR3 has a longer functional half-life than IGF-1 DES. DES is faster-acting and reaches high receptor availability quickly, but that activity window is shorter and the reconstituted peptide is comparatively less stable over time. |
Receptor Binding & Potency in Research Models
"Potency" gets used loosely when comparing these two peptides, so it's worth separating two different claims that show up in the literature and in vendor marketing:
- Binding-protein resistance — both LR3 and DES show substantially reduced IGFBP affinity compared to native IGF-1, which is the property that makes them useful research tools in the first place.
- Receptor availability over time — DES is often described as reaching a higher proportion of free, receptor-available peptide quickly after introduction to a research system, while LR3's advantage is sustaining receptor engagement over a longer window rather than peaking faster.
Neither analogue is straightforwardly "more potent" in every research context — it depends on assay design, exposure duration, and what the study is actually measuring. A short-window in vitro signaling assay and a multi-day proliferation study call for different tradeoffs between rapid receptor availability and sustained activity, which is exactly why this comparison matters before ordering either peptide.
Choosing Between IGF-1 LR3 and IGF-1 DES for Your Study
The right analogue depends on what your protocol is actually designed to measure. A few practical questions can help narrow the decision:
13.1 Choose IGF-1 LR3 when:
- The study design requires sustained IGF-1 receptor signaling over an extended observation window
- Reconstituted peptide will be used across multiple sessions rather than immediately
- The research question involves longer-duration cell proliferation or growth-signaling assays
13.2 Choose IGF-1 DES when:
- The protocol calls for a short, high-availability exposure window
- The study design benefits from closer structural similarity to native IGF-1
- Peptide will be reconstituted and used promptly within the same research session
Researcher Checklist Before ordering either analogue, confirm: (1) your assay's required exposure window, (2) whether the study needs sustained vs. rapid receptor engagement, (3) your lab's cold-chain and same-day-use capability, and (4) that your supplier provides a batch-specific Certificate of Analysis. |
Purity, Testing & Certificates of Analysis
Structural comparisons only matter if the peptide you're working with is actually what the label says it is. Peptide purity and identity should be independently verifiable, not just claimed — this is a core part of Google's E-E-A-T standard as applied to research chemical suppliers, and it directly affects whether your results are reproducible.
At minimum, look for the following from any IGF-1 LR3 or IGF-1 DES supplier:
- A batch-specific Certificate of Analysis (COA), not a generic or outdated one
- Purity verification via HPLC (high-performance liquid chromatography)
- Identity confirmation via mass spectrometry
- Third-party lab testing rather than in-house-only results
- Clear Research Use Only (RUO) labeling and documentation
99 Purity Peptides batch-tests its research peptide catalog and provides Certificates of Analysis for verification — a baseline researchers should expect from any domestic USA peptide supplier before basing a study on a given lot.
Storage, Reconstitution & Handling Best Practices
Both IGF-1 LR3 and IGF-1 DES are lyophilized (freeze-dried) peptides prior to reconstitution, and both require careful handling to preserve activity.
Before reconstitution
- Store lyophilized peptide powder frozen, away from light and moisture, until ready for use
- Allow vials to reach room temperature before opening to avoid condensation inside the vial
Reconstitution
- Use bacteriostatic water (or the diluent specified for your protocol) as the reconstitution liquid
- Add the diluent slowly, directing the stream against the vial wall rather than directly onto the lyophilized powder
- Gently swirl to dissolve — do not shake, which can degrade peptide structure
- Label the vial with reconstitution date and concentration for traceability
After reconstitution
- Refrigerate reconstituted peptide and avoid repeated freeze-thaw cycles
- Because IGF-1 DES is comparatively less stable in solution, plan to use it closer to the point of reconstitution than you might with IGF-1 LR3
- Discard any solution showing discoloration, precipitation, or cloudiness
Research Use Only Compliance & Safety
IGF-1 LR3 and IGF-1 DES are sold and distributed strictly for laboratory and in-vitro research applications. They are not approved by the FDA for human or animal use, are not dietary supplements, and are not intended for diagnostic or therapeutic administration outside of a qualified research setting.
- Products should only be handled by qualified personnel in an appropriate laboratory environment
- Every order should be accompanied by RUO documentation and, where applicable, a Safety Data Sheet (SDS)
- Researchers should follow their institution's protocols for handling and disposing of research peptides
Common Mistakes Researchers Make When Comparing IGF-1 Analogues
- Treating "IGFBP-resistant" as identical to "identical half-life" — both analogues resist IGFBPs, but through different mechanisms with different durations of effect
- Reconstituting more peptide than will be used in a single research session, especially with the less stable IGF-1 DES
- Sourcing from a supplier without batch-specific COAs, making purity assumptions instead of verifying them
- Assuming published potency claims from one assay design transfer directly to a different study format
- Skipping documentation of reconstitution date and storage conditions, which undermines reproducibility
Key Takeaways
- IGF-1 LR3 adds a 13-amino-acid N-terminal extension; IGF-1 DES removes the first 3 amino acids from native IGF-1 — opposite structural strategies aimed at the same IGFBP-resistance goal
- IGF-1 LR3 generally shows a longer functional half-life; IGF-1 DES shows faster but shorter-duration receptor availability
- Neither analogue is universally "more potent" — the right choice depends on your assay's exposure window and research design
- IGF-1 DES is comparatively less stable once reconstituted and should be used promptly
- Purity verification (HPLC, mass spectrometry, third-party COA) matters as much as which analogue you choose
- Both peptides are Research Use Only and are not intended for human or animal consumption
Frequently Asked Questions
What is the main difference between IGF-1 LR3 and IGF-1 DES?
IGF-1 LR3 adds a 13-amino-acid extension to the N-terminus of IGF-1, while IGF-1 DES removes the first three amino acids. Both reduce IGFBP binding, but LR3 produces a longer functional half-life and DES produces faster, shorter-duration receptor availability.
Which IGF-1 analogue has a longer half-life, LR3 or DES?
IGF-1 LR3 has the longer functional half-life of the two, largely because its N-terminal extension provides stronger and more sustained resistance to IGFBP binding.
Is IGF-1 LR3 more potent than standard IGF-1?
IGF-1 LR3 shows greater sustained receptor availability than native IGF-1 in research models because it largely escapes IGFBP sequestration, allowing more free peptide to remain active over time.
Is IGF-1 DES more potent than standard IGF-1?
IGF-1 DES is often reported as reaching higher short-term receptor availability than native IGF-1, though its activity window is shorter than IGF-1 LR3's.
How do IGF-1 LR3 and IGF-1 DES differ in receptor binding?
Both analogues retain strong affinity for the IGF-1 receptor while showing much lower affinity for IGFBPs compared to native IGF-1. The practical difference lies in how long that receptor engagement is sustained, not whether binding occurs.
Why do researchers use IGF-1 LR3 instead of native IGF-1?
Native IGF-1 is quickly bound by IGFBPs in solution, which limits predictable exposure in a research system. IGF-1 LR3's structural modification reduces that binding, giving researchers a more sustained and controllable activity window.
Why do researchers use IGF-1 DES instead of native IGF-1?
IGF-1 DES offers similarly reduced IGFBP binding through N-terminal truncation, while remaining closer in size to native IGF-1 — a structural consideration for certain study designs that call for faster, more immediate receptor availability.
How should I store IGF-1 LR3 and IGF-1 DES peptides?
Store lyophilized powder frozen and protected from light and moisture. Once reconstituted, refrigerate and avoid repeated freeze-thaw cycles; use IGF-1 DES promptly given its comparatively lower solution stability.
How long can reconstituted IGF-1 LR3 be kept refrigerated?
Reconstituted IGF-1 LR3 is generally more stable under refrigeration than IGF-1 DES, but exact duration depends on your specific protocol, diluent, and storage conditions — always follow your lab's validated stability data.
How long can reconstituted IGF-1 DES be kept refrigerated?
IGF-1 DES is comparatively less stable in solution than IGF-1 LR3, so researchers typically plan to use reconstituted DES closer to the point of preparation rather than storing it for extended periods.
What is the recommended reconstitution liquid for IGF-1 peptides?
Bacteriostatic water is the standard reconstitution diluent for both IGF-1 LR3 and IGF-1 DES in most research protocols, added slowly against the vial wall rather than directly onto the lyophilized powder.
Does 99 Purity Peptides test every batch for purity?
Yes. 99 Purity Peptides batch-tests its research peptide catalog and provides a Certificate of Analysis (COA) with HPLC and mass spectrometry verification for purity and identity.
Are IGF-1 LR3 and IGF-1 DES intended for human use?
No. Both peptides are sold strictly for laboratory and in-vitro research purposes and are not intended for human or animal consumption, diagnostic use, or therapeutic administration.
Can IGF-1 LR3 and IGF-1 DES be shipped within the USA?
99 Purity Peptides ships research peptides domestically within the USA with appropriate cold-chain handling; check current shipping policy on the site for specifics.
How do I choose between IGF-1 LR3 and IGF-1 DES for my study?
Match the analogue to your assay's exposure window: choose IGF-1 LR3 for studies needing sustained signaling over a longer period, and IGF-1 DES for protocols requiring rapid, short-window receptor availability.
